While relapse in multiple myeloma (MM) is inevitable, the agents available to keep it under control are rapidly expanding and providing patients with improved duration and quality of life. In this case-based activity, an expert in MM reviews current strategies for optimizing care—including the clinical application of newer therapies recently added to the treatment armamentarium, and management of their adverse events.
Identify characteristics of relapsed/refractory (RR) MM and guideline-recommended treatment strategies
Summarize considerations for individualizing RRMM therapy with novel agents
Address disease- and treatment-related complications in patients with RRMM, including adverse events from novel agents
This activity is supported by an educational grant from GlaxoSmithKline and Oncopeptides.
Dr Patel: consultant/speakers bureau: Bristol-Myers Squibb/Celgene; speakers bureau: Amgen, Janssen Pharmaceuticals.
© 2021 Practicing Clinicians Exchange. All Rights Reserved. 98220O-7A